CLOVER BIO-B(02197),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02197 CLOVER BIO-B

Noon Closed 09-17 11:57:01

1.985

+0.025

+1.28%

High2.000	Low1.950	Vol543.00K
Open1.955	D1 Closing1.960	Amplitude2.55%
Mkt Cap2.58B	Tradable Cap2.58B	Total Shares1.30B
T/O1.07M	T/O Rate0.04%	Tradable Shares1.30B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02197","market":"HK","secType":"STK","nameCN":"CLOVER BIO-B","latestPrice":1.985,"timestamp":1789617421987,"preClose":1.96,"halted":0,"volume":543000,"delay":0,"changeRate":0.012755102040816394,"floatShares":1299000000,"shares":1299000000,"eps":-0.19030935894056364,"marketStatus":"Noon Closed","change":0.025,"latestTime":"09-17 11:57:01","open":1.955,"high":2,"low":1.95,"amount":1072070,"amplitude":0.02551,"askPrice":1.985,"askSize":9500,"bidPrice":1.97,"bidSize":18500,"shortable":0,"etf":0,"ttmEps":0.7821636996171469,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789621200000},"marketStatusCode":3,"adr":0,"listingDate":1636041600000,"exchange":"SEHK","adjPreClose":1.96,"openAndCloseTimeList":[[1789608600000,1789617600000],[1789621200000,1789632000000]],"volumeRatio":0.278615,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02197","defaultTab":"news","newsList":[{"id":"1121573888","title":"Greenland Holdings' Half-Year Report Contains Multiple Elementary Errors Including a Misnamed Province; Board Secretary Wang Xiaodong Has Earned 44.85 Million Yuan Over an 11-Year Tenure","url":"https://stock-news.laohu8.com/highlight/detail?id=1121573888","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121573888?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:30","pubTimestamp":1789450228,"startTime":"0","endTime":"0","summary":"Recent disclosures of half-year reports have brought attention to textual mistakes in corporate filings. Real estate developer Greenland Holdings Corporation Limited (600606.SH) has issued its 2026...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0277","BK0187","BK0028","BK0012","BK1161","600606","BK0178","BK0116","02197","BK0101","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100521924","title":"Clover Biopharmaceuticals-B Surges Over 6% on Positive Phase II Data for Respiratory Combination Vaccine in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=1100521924","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100521924?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:58","pubTimestamp":1789369093,"startTime":"0","endTime":"0","summary":"Shares of Clover Bio-B (02197) climbed more than 6% during the afternoon trading session. As of the latest update, the stock was up 5.24% to HK$2.01, with trading volume reaching HK$5.486 million.The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1161","BK4588","KCAI","VXUS","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128997616","title":"Hong Kong Stock Pulse | Clover Biopharma Soars Over 9% in Morning Session on Positive Phase II Data for Respiratory Combination Vaccine in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=1128997616","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128997616?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:06","pubTimestamp":1788923176,"startTime":"0","endTime":"0","summary":"Shares of CLOVER BIO-B (02197) surged more than 9% during Tuesday's morning trading session before paring gains to trade up 7.62% at HK$2.26, with turnover reaching HK$10.41 million.The sharp uptick...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4585","KCAI","BK1161","02197","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322978","title":"Cloverleaf Bio: Round Led by 4Bio Capital; Participation from Abbvie Ventures, Eli Lilly and Company, Among Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322978?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865217,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN450020:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665394100","title":"Clover Biopharma's Respiratory Illness Vaccines Show Promise in Phase II Australian Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2665394100","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665394100?lang=en_us&edition=fundamental","pubTime":"2026-09-07 14:29","pubTimestamp":1788762559,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals  has disclosed positive results from its phase 2 Australia trials evaluating two vaccine combinations to potentially treat respiratory illnesses in adults, according to a Hong Kong Exchange filing from Monday.The company said the groups receiving the combinations SCB-1022 and SCB-1033 saw the rate of respiratory tract infection decline by 62% when compared to placebo. The combinations were generally well tolerated, with side effects including fatigue, headache, and pain at the injection site.Clover also said it increased production of the vaccine candidates during the trial, which it believes will help with late-stage testing and commercialization. Based on the latest trial results, the company plans further testing and is seeking partners for a global collaboration.The company's shares were up nearly 2% in afternoon trading on the HKEX.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","IMLC.AU","GIVE.AU","IOZ.AU","SLF.AU","QFN.AU","EIGA.AU","STW.AU","BEAR.AU","IISV.AU","BBOZ.AU","OZR.AU","XJO.AU","E200.AU","VAP.AU","DACE.AU","VAS.AU","XKO.AU","QRE.AU","02197","OZF.AU","XAO.AU","IIGF.AU","GEAR.AU","ZYAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665063367","title":"Clover Biopharma Reports Positive Phase 2 Data for RSV-hMPV Combination Vaccine in Older Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2665063367","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665063367?lang=en_us&edition=fundamental","pubTime":"2026-09-07 07:08","pubTimestamp":1788736125,"startTime":"0","endTime":"0","summary":"Clover Biopharma reports positive Phase 2 data for RSV-hMPV combination vaccine in older adultsClover Biopharmaceuticals announced positive preliminary Phase 2 results from an Australia trial of two c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nNDL4Djd9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665036705","title":"Clover Announces Positive Phase 2 Clinical Data for Rsv + Hmpv ± Piv3 Respiratory Combination Vaccine Candidates in Older Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2665036705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665036705?lang=en_us&edition=fundamental","pubTime":"2026-09-07 07:08","pubTimestamp":1788736110,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nTUA97RLLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715724","title":"Clover Biopharma Returns to Profit in H1 FY26 at RMB 954.98 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715724","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715724?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:43","pubTimestamp":1787744594,"startTime":"0","endTime":"0","summary":"Clover Biopharma returns to profit in H1 FY26 at RMB 954.98 millionClover Biopharmaceuticals swung to an IFRS profit of RMB 954.98 million, reflecting a one-off GAVI settlement gain.Revenue fell 94.5%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4d5M8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139951385","title":"Clover Biopharmaceuticals Flips to Profit in First-Half Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1139951385","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139951385?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:40","pubTimestamp":1787697612,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals-B (02197) reported a net profit attributable to parent shareholders of 955 million yuan for the six months ended June 30, 2026, marking a turnaround from a loss in the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142078584","title":"Clover posts RMB0.95 billion interim profit for H1 2026, propelled by one-off GAVI settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=1142078584","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142078584?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:26","pubTimestamp":1787696765,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals (Clover) reported a sharp earnings turnaround for the six months ended 30 June 2026, booking net profit of RMB0.95 billion versus a RMB0.10 billion loss a year earlier. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Clover posts RMB0.95 billion interim profit for H1 2026, propelled by one-off GAVI settlement","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662505547","title":"China's Clover Biopharma H1 Revenue Drops Sharply, Flags Going-Concern Doubt","url":"https://stock-news.laohu8.com/highlight/detail?id=2662505547","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662505547?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:24","pubTimestamp":1787696645,"startTime":"0","endTime":"0","summary":"China's Clover Biopharma H1 revenue drops sharply, flags going-concern doubtOverviewChina vaccine developer's H1 revenue dropped sharply after ending AdimFlu-S (QIS) sales in ChinaCompany swung to net","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","02197","06118","LU0502904849.HKD","LU2097828805.USD","01801","LU0326950275.SGD","KURE","LU2328871848.SGD","LU2097828474.EUR","LU1969619763.USD","BK1583","BK1589","HK0000165453.HKD","LU0455707207.USD","LU2097828557.USD","LU1188198961.HKD","BK1141","LU2097828631.EUR","LU2488822045.USD","BK1161","LU2097828714.EUR","LU0463099449.HKD","LU0244354667.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775779","title":"Clover Biopharmaceuticals H1 Revenue RMB 179 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775779?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:09","pubTimestamp":1787695742,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLX5WMNXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198595840","title":"Clover Biopharmaceuticals Sets 25 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1198595840","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198595840?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:07","pubTimestamp":1786612025,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals has scheduled a board meeting for Tuesday, 25 August 2026 in Shanghai. Directors will review and approve the consolidated interim results for the six months ended 30 June...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659132135","title":"Clover Biopharma Sets Board Meeting to Review Interim Results, Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2659132135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659132135?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:32","pubTimestamp":1786609940,"startTime":"0","endTime":"0","summary":"Clover Biopharma sets board meeting to review interim results, consider dividendClover Biopharmaceuticals will hold a board meeting on Aug. 25, 2026.Directors will review interim results for the six m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6Mck2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654055822","title":"With Clover Biopharmaceuticals Up 10%, Insider Buyers Count Their Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2654055822","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654055822?lang=en_us&edition=fundamental","pubTime":"2026-07-25 07:34","pubTimestamp":1784936049,"startTime":"0","endTime":"0","summary":"Insiders who bought Clover Biopharmaceuticals, Ltd. ( HKG:2197 ) stock in the last 12 months were richly rewarded last...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2197/clover-biopharmaceuticals-shares/news/with-clover-biopharmaceuticals-up-10-insider-buyers-count-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2197/clover-biopharmaceuticals-shares/news/with-clover-biopharmaceuticals-up-10-insider-buyers-count-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653120917","title":"Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2653120917","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653120917?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:41","pubTimestamp":1784648515,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemiaCellectar BioSciences outlined plan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL6R2kRw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB","BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108650143","title":"CLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1108650143","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108650143?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:10","pubTimestamp":1784502621,"startTime":"0","endTime":"0","summary":"The biotechnology firm CLOVER BIO-B (02197) has issued a positive profit alert for the first half of the year.For the six-month period ending June 30, 2026, the group expects to record a net profit...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652268549","title":"Clover Biopharmaceuticals - Expects Net Profit of Rmb957 Mln–rmb1204 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652268549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652268549?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:04","pubTimestamp":1784502272,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nFWN43J0TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198338149","title":"Clover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1198338149","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198338149?lang=en_us&edition=fundamental","pubTime":"2026-07-03 17:24","pubTimestamp":1783070663,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals, Ltd. released its monthly return for the period ended 30 June 2026, confirming that the company’s capital structure was unchanged during the month. The authorised share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159240019","title":"CLOVER BIO-B Adopts Sixth Amended & Restated Memorandum and Articles of Association; Authorised Share Capital Fixed at US$0.20 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1159240019","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159240019?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:04","pubTimestamp":1781791489,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals, Ltd. (“Clover Bio-B”, HKEX: 02197) has approved its Sixth Amended and Restated Memorandum and Articles of Association (“6th M&A”) by special resolution dated 18 June 2026....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cloverbiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0841},{"period":"1month","weight":-0.1211},{"period":"3month","weight":0.2327},{"period":"6month","weight":-0.0755},{"period":"1year","weight":0.0155},{"period":"ytd","weight":-0.1624}],"compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":-0.0291},{"period":"3month","weight":0.033},{"period":"6month","weight":-0.0223},{"period":"1year","weight":-0.0652},{"period":"ytd","weight":-0.0358}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Clover Biopharmaceuticals Ltd is an investment holding company primarily engaged in the research and development, manufacture and commercialization of innovative vaccines. The Company’s products and candidates include Respiratory Syncytial Virus (RSV) Vaccine (SCB-1019), seasonal quadrivalent influenza vaccine AdimFlu-S, SCB-219M, COVID-19 Vaccine and others. The Company leverages the Trimer-Tag technology platform to conduct research and development (R&D) for innovative vaccines that can fulfill unmet need, with a focus on building a respiratory vaccine franchise and establishing a presence in the pediatric vaccine market. The Trimer-Tag is a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.113925},{"month":2,"riseRate":0.4,"avgChangeRate":0.011169},{"month":3,"riseRate":0.2,"avgChangeRate":-0.104268},{"month":4,"riseRate":0.4,"avgChangeRate":-0.028136},{"month":5,"riseRate":0.4,"avgChangeRate":-0.154826},{"month":6,"riseRate":0.4,"avgChangeRate":-0.025093},{"month":7,"riseRate":0.6,"avgChangeRate":0.169081},{"month":8,"riseRate":0.6,"avgChangeRate":0.078417},{"month":9,"riseRate":0.4,"avgChangeRate":0.250175},{"month":10,"riseRate":0,"avgChangeRate":-0.070872},{"month":11,"riseRate":0.75,"avgChangeRate":0.569272},{"month":12,"riseRate":0.2,"avgChangeRate":-0.160916}],"exchange":"SEHK","name":"CLOVER BIO-B","nameEN":"CLOVER BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLOVER BIO-B(02197),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLOVER BIO-B(02197) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLOVER BIO-B,02197,CLOVER BIO-B股票,CLOVER BIO-B股票老虎,CLOVER BIO-B股票老虎国际,CLOVER BIO-B行情,CLOVER BIO-B股票行情,CLOVER BIO-B股价,CLOVER BIO-B股市,CLOVER BIO-B股票价格,CLOVER BIO-B股票交易,CLOVER BIO-B股票购买,CLOVER BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLOVER BIO-B(02197),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLOVER BIO-B(02197) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}